π¬π Encouraging News in Metastatic Uveal Melanoma Research!
New clinical trial results are offering hope for the ocular melanoma community! A Phase 1/2 study evaluating the combination of brenetafusp and tebentafusp (KIMMTRAK) reported an estimated 70% two-year survival rate among 17 patients receiving the treatment as their first systemic therapy. While these are early results from a small study, they represent an exciting step forward in the search for better treatment options. Researchers are planning a larger trial to further evaluate this combination. Every advancement in research brings us closer to better outcomes for patients and families. π π Read more: https://www.techtimes.com/articles/330210/20261106/uveal-melanoma-dual-t-cell-drugs-hit-70-two-year-survival-where-checkpoint-drugs-failed.htm #OcularMelanoma #UvealMelanoma #CancerResearch #RareCancer #ACureInSightSee it on Instagram β